Kaya Holdings, Inc.

OTC:KAYS

Pharmaceutical Preparations·FORT LAUDERDALE, FL

Summary Financials

Revenue

$7,134

-99.0% YoY

FY 2024

Adj. EBITDA

-$1.0M

-14170.2% margin

FY 2024

Net Income

$1.6M

22563.7% margin

FY 2024

EPS (Diluted)

$0.01

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$18,330

FY 2023

Total Debt

$672,800

FY 2013

Net Debt

$654,470

FY 2013

Enterprise Value

—

Debt / EBITDA

-0.6x

FY 2024

EV / EBITDA

—

Employees

—

Revenue

$7,134

-99.0% YoY

FY 2024

Adj. EBITDA

-$1.0M

-14170.2% margin

FY 2024

Net Income

$1.6M

22563.7% margin

FY 2024

EPS (Diluted)

$0.01

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$18,330

FY 2023

Total Debt

$672,800

FY 2013

Net Debt

$654,470

FY 2013

Enterprise Value

—

Debt / EBITDA

-0.6x

FY 2024

EV / EBITDA

—

Employees

—